Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Lymphadenopathy: early-phase trial registry

A small indexed set (6 trials) with no open enrollment listed right now.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · none currently recruiting · #2,866 of 28,707 conditions by registered trial count

Lymphadenopathy: 6 US clinical trials tracked, none currently recruiting.

Lymphadenopathy is the subject of 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Mauna Kea Technologies, running 1 of these trials.

Enrollment posture brief

Registry condition lymphadenopathy

OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #2866 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Lymphadenopathy (this)0%
Open-enrollment share among volume-matched conditions near Lymphadenopathy

Lymphadenopathy has no open enrollment in this registry pull (6 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lymphadenopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lymphadenopathy is recruiting below its size-band peers.

    0 of 6 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Lymphadenopathy research.

    Mauna Kea Technologies accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Lymphadenopathy trials plan to enrol fewer than 100 people.

    Median target enrolment is 62 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. Lymphadenopathy research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22

Phase Distribution

PhaseTrial count
Phase 2 2

Named interventions

Most-linked intervention names on Lymphadenopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Laboratory Biomarker Analysis Other
3 trials
Endobronchial Ultrasound Procedure
1 trials
Fine needle biopsy Device
1 trials
Fine needle aspiration Device
1 trials
Ex Vivo-activated Autologous Lymph Node Lymphocytes Biological
1 trials
Endoscopic ultrasound fine needle aspiration Device
1 trials
Retroperitoneal Lymph Node Dissection Procedure
1 trials
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine Biological
1 trials

US sites by state

Facility locations filed on Lymphadenopathy trials. A trial with sites in several states counts in each.

Texas 3 trials
California 3 trials
Maryland 2 trials
Georgia 2 trials
Washington 1 trials
Pennsylvania 1 trials
Oklahoma 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lymphadenopathy page

6 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Lymphadenopathy trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Mauna Kea Technologies sponsors the most Lymphadenopathy trials on record, review their full trial history before evaluating a specific study. See Mauna Kea Technologies's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphadenopathy condition card totals 6 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.